Stock SNPX SYNAPTOGENIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Synaptogenix, Inc. Other OTC

Equities

SNPX

US87167T1025

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery
PR
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
PR
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics
PR
Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.
CI
Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall
MT
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
PR
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders
PR
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
PR
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by the Technion, Israel Institute of Technology
AQ
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology
PR
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.
CI
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)
AQ
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease
PR
Synaptogenix : Certificate of Incorporation/Bylaws - Form 8-K
PU
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study
PR
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNPX Stock
  4. SNPX Stock
  5. News Synaptogenix, Inc.